Horstmann M, Merseburger A S, Stenzl A, Kuczyk M
Klinik für Urologie, Eberhard-Karls-Universität, Tübingen, Germany.
Urologe A. 2006 May;45(5):605-8. doi: 10.1007/s00120-006-1038-2.
Systemic treatment of advanced-stage adrenal malignancies is most often only palliative. Mitotane alone or in combination with other chemotherapeutic agents such as cisplatin, etoposide, and vincristine are established therapeutic concepts for the treatment of metastatic adrenal cancer. Suramin and gossypol are rarely employed. New therapeutic options are tumor vaccination and treatment with antiangiogenic drugs. Metaiodobenzylguanidine as a radiotherapeutic drug or chemotherapeutic combination therapies that include cyclophosphamide, vincristine, and dacarbazine are applied for systemic treatment of malignant pheochromocytomas.. However, the clinical efficacy of the latter regimen needs further evaluation.
晚期肾上腺恶性肿瘤的全身治疗通常仅具有姑息作用。米托坦单独使用或与其他化疗药物(如顺铂、依托泊苷和长春新碱)联合使用是治疗转移性肾上腺癌的既定治疗理念。苏拉明和棉酚很少使用。新的治疗选择是肿瘤疫苗接种和抗血管生成药物治疗。间碘苄胍作为一种放射治疗药物或包括环磷酰胺、长春新碱和达卡巴嗪在内的化疗联合疗法被用于恶性嗜铬细胞瘤的全身治疗。然而,后一种方案的临床疗效需要进一步评估。